Lessons for reviewing clinical trials using induced pluripotent stem cells: examining the case of a first-in-human trial for age-related macular degeneration

In this commentary from Regenerative Medicine, learn more about the pilot first-in-human study conducted by Masayo Takahashi, RIKEN (Japan).

Go to the profile of Regenerative Medicine
Feb 28, 2018
0
0
Like 0 Comment

In 2014, Dr Masayo Takahashi (RIKEN, Kobe, Japan) and her research team conducted the first-in-human (FIH) trial using induced pluripotent stem cells (iPSCs). In this pilot case, a sheet of retinal pigment epithelial cells was transplanted into a patient. Along with the ambition of the Japanese government, which sought to dominate the global field of regenerative medicine, the news of this trial attracted great attention to diverse communities such as patients, the general public and stem cell researchers. This mounting excitement about regenerative medicine as a ‘dream therapy’, however, put the five committees reviewing the iPSC-FIH trial under significant stress during the review process from 2012-2013.

"There was no doubt that each review committee experienced extreme pressure to grant an approval"

In this Regenerative Medicine commentary, the minutes of the iPSC-FIH trial review committee meetings were examined to identify future lessons for the committees reviewing cutting-edge FIH trials using novel stem cells.

Takashima K, Inoue Y, Tashiro S, Muto K. Lessons for reviewing clinical trials using induced pluripotent stem cells: examining the case of a first-in-human trial for age-related macular degeneration. Regen. Med. (2018)(Epub ahead of print)

Go to the profile of Regenerative Medicine

Regenerative Medicine

Journal, Future Science Group

Regenerative Medicine is an award-winning peer-reviewed journal, in print and web formats. The journal provides a forum to address the important challenges and advances in stem cell research and regenerative medicine, delivering this essential information in concise, clear and attractive article formats. Among other indexing services Regenerative Medicine is listed by MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Science Citation Index Expanded™ (SciSearch®), Emcare, Biological Abstracts, BIOSIS Previews, Biotechnology Citation Index®, Journal Citation Reports/Science Edition®, Scopus® with an Impact Factor of 2.786 (2014). Each issue contains expertly drafted Reviews, Original Research articles, Perspectives, Editorials, topical insight from international leaders in their field, and additional added-value content. The Senior Editor of the journal is Professor Chris Mason, University College London. You can find out more about Regenerative Medicine at our website (www.future-science-group.com/journalprofile/regenerative-medicine/), where you can find the aims and scope of the journal and details of our international editorial board.

No comments yet.